J Clin Oncol: The efficacy of nivolumab combined with low-dose ipilimumab in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer

Based on the CheckMate 142 study, Nivolumab was approved by the US FDA as a single agent or combined with Ipilimumab for the treatment of high microsatellite instability/mismatch repair defects (MSI-H/dMMR) Of metastatic colorectal cancer (mCRC) that has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan
.

FDA colorectal cancer

This article reports the results of nivolumab combined with low-dose ipilimumab as a first-line treatment for MSI-H/dMMR CRC patients in the Phase II CheckMate 142 study
.

Patients with previously untreated metastatic MSI-H/dMMR CRC received nivolumab (1 time/2 weeks) combined with low-dose ipilimumab (1 time/6 weeks) until the disease progressed
.

The primary endpoint is the objective response rate

Progression-free survival

A total of 45 patients were recruited, with a median age of 66 years
.

The median follow-up was 29.

The objective response rate and disease control rate were 69% (95% CI 53-82) and 84% (95% CI 70.

Overall survival rate

At the shortest follow-up of 24.
2 months, neither the median progression-free survival nor the median overall survival was reached; the progression-free survival rate and overall survival rate at 24 months were 74% and 79%, respectively
.

Regardless of baseline demographics and tumor characteristics (including BRAF and KRAS mutation status), clinical benefit was observed

The progression-free survival rate and overall survival rate at 24 months were 74% and 79%, respectively.

The occurrence of adverse events

22% of patients experienced grade 3-4 treatment-related adverse events; 13% of patients discontinued treatment due to treatment-related adverse events
.

In summary, nivolumab combined with low-dose ipilimumab as a first-line treatment has shown strong and lasting clinical benefits and good tolerability in patients with MSI-H/dMMR mCRC
.

Based on these data, relevant randomized trials can be further carried out

Wu satisfied monoclonal antibody combined with low doses of ipilimumab as first-line therapy demonstrated a powerful and long-lasting clinical benefit and well tolerated in MSI-H / dMMR mCRC patients satisfied Wu monoclonal antibody combined with low doses of ipilimumab as The first-line treatment has demonstrated strong and long-lasting clinical benefits and good tolerability in patients with MSI-H/dMMR mCRC

Original source:

Original source:

Heinz-Josef Lenz, et al.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High / Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study in this message